Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announces CEO Emil D. Kakkis will present virtually at the Jefferies Virtual Gene Therapy/Editing Summit on October 2, 2020, at 1:00 PM ET. The presentation will be accessible live and as an archive on their website. Ultragenyx focuses on developing treatments for serious rare and ultra-rare genetic diseases, with a commitment to efficient drug development. They aim to provide safe and effective therapies to patients with high unmet medical needs. Visit their website for more details.
- None.
- None.
NOVATO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will hold a virtual presentation at the Jefferies Virtual Gene Therapy/Editing Summit on Friday, October 2, 2020 at 1:00 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-660-0951
FAQ
When will Ultragenyx present at the Jefferies Virtual Gene Therapy/Editing Summit?
Who is presenting for Ultragenyx at the summit?
Where can I watch the Ultragenyx presentation?
What is Ultragenyx focused on?
What is the ticker symbol for Ultragenyx?
